Insulet (NSDQ:PODD) said today that it inked deals with two partners, Theras Group and Nordic Infucare, to distribute its tubeless insulin pump, Omnipod, in Italy and the Nordic markets starting July 1.
According to the agreements, both distributors will provide sales, marketing and customer support for Omnipod users and providers in Italy and the Nordic markets. No financial terms of the deals were disclosed.
“There are considerable commercial opportunities for the Omnipod System in Italy and the Nordics and we are thrilled to work with these two highly-experienced and respected diabetes medical device companies that have provided support to the local diabetes communities for many years,” DJ Cass, general manager of Insulet’s Europe operations, said in prepared remarks. “Establishing these partnerships is another critical step forward to ensure Insulet’s smooth transition to direct operations in Europe and provides a platform for long-term growth and an exceptional customer experience.”
“Omnipod is a perfect fit within our existing diabetes portfolio and we are excited to partner with Insulet to provide support to Omnipod System users in Sweden, Norway, Denmark and Finland and to continue building awareness and knowledge of this unique insulin pump across our region,” Mats Durvall, general manage of Nordic Infucare, added.
“We are also delighted to add the Omnipod System, the leading tubeless insulin pump technology, to our diabetes portfolio so we can offer greater options and support for people living with diabetes in Italy,” Cristiano Ferrari, president of Theras Group, said.
